Bellevue Group Ag Bristol Myers Squibb CO Transaction History

Bellevue Group Ag

$4.67 Billion
Q3 2025

A detailed history of Bellevue Group Ag transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bellevue Group Ag holds 47,613 shares of BMY stock, worth $2.23 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

47,613

Previous 37,177 28.07%

Holding current value

$2.23 Million

Previous $1.72 Million 24.83%

% of portfolio

0.05%

Previous 0.04%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$43.31 - $48.98 $451,983 - $511,155	10,436 Added 28.07%	47,613 $2.15 Million
Q2 2025 Aug 14, 2025	BUY	$44.12 - $59.6 $512,277 - $692,015	11,611 Added 45.42%	37,177 $1.72 Million
Q1 2025 May 14, 2025	SELL	$53.9 - $63.11 $676,283 - $791,841	-12,547 Reduced 32.92%	25,566 $1.56 Million
Q4 2024 Feb 14, 2025	BUY	$51.92 - $59.94 $66,872 - $77,202	1,288 Added 3.5%	38,113 $2.16 Million
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $1.46 Million - $1.91 Million	36,825 New	36,825 $1.91 Million

Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $1.12 Million - $1.27 Million	23,436 New	23,436 $1.27 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $3.2 Million - $3.63 Million	-48,759 Reduced 97.02%	1,496 $103,000
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $2.96 Million - $3.5 Million	43,193 Added 611.63%	50,255 $3.62 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $2,319 - $1.37 Million	-17,845 Reduced 71.65%	7,062 $502,000
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $43.8 Million - $48.2 Million	-603,221 Reduced 96.03%	24,907 $1.92 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $26.5 Million - $31.8 Million	-431,219 Reduced 40.71%	628,128 $45.9 Million
Q4 2021 Feb 10, 2022	SELL	$53.63 - $62.52 $13.1 Million - $15.2 Million	-243,587 Reduced 18.7%	1,059,347 $66.1 Million
Q3 2021 Nov 12, 2021	SELL	$59.17 - $69.31 $9.5 Million - $11.1 Million	-160,498 Reduced 10.97%	1,302,934 $77.1 Million
Q2 2021 Aug 12, 2021	SELL	$61.91 - $67.42 $38.5 Million - $41.9 Million	-621,720 Reduced 29.82%	1,463,432 $97.8 Million
Q1 2021 May 12, 2021	BUY	$59.34 - $66.74 $16.7 Million - $18.7 Million	280,680 Added 15.55%	2,085,152 $132 Million
Q4 2020 Feb 16, 2021	BUY	$57.74 - $65.43 $9.16 Million - $10.4 Million	158,560 Added 9.63%	1,804,472 $112 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $1.94 Million - $2.15 Million	33,800 Added 2.1%	1,645,912 $99.2 Million
Q2 2020 Aug 13, 2020	BUY	$54.82 - $64.09 $22.3 Million - $26.1 Million	406,640 Added 33.73%	1,612,112 $94.8 Million
Q1 2020 May 14, 2020	SELL	$46.4 - $67.43 $41 Million - $59.6 Million	-883,770 Reduced 42.3%	1,205,472 $67.2 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $56.7 Million - $74 Million	1,152,233 Added 122.97%	2,089,242 $134 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $3.48 Million - $4.13 Million	81,400 Added 9.51%	937,009 $47.5 Million
Q2 2019 Aug 14, 2019	BUY	$44.62 - $49.34 $7.13 Million - $7.88 Million	159,785 Added 22.96%	855,609 $38.8 Million
Q1 2019 May 15, 2019	BUY	$45.12 - $53.8 $9.43 Million - $11.2 Million	209,000 Added 42.93%	695,824 $33.2 Million
Q4 2018 Feb 12, 2019	BUY	$48.76 - $63.23 $7.07 Million - $9.17 Million	145,095 Added 42.46%	486,824 $25.3 Million
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $4.46 Million - $5.03 Million	80,880 Added 31.01%	341,729 $21.2 Million
Q2 2018 Aug 07, 2018	BUY	$50.53 - $62.98 $11.2 Million - $13.9 Million	220,849 Added 552.12%	260,849 $14.4 Million
Q1 2018 May 09, 2018	BUY	$59.92 - $68.98 $2.4 Million - $2.76 Million	40,000 New	40,000 $2.53 Million

Others Institutions Holding BMY

# of Institutions

2,680

Shares Held

1.58B

Call Options Held

28M

Put Options Held

28.4M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.5B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.

Account

Bellevue Group Ag Bristol Myers Squibb CO Transaction History